2025-07-14 09:15Current Period Performance Forecast The company expects a 17.3% to 25.2% year-on-year decrease in H1 2025 operating revenue, but net profit attributable to shareholders will turn profitable, primarily due to fair value changes in biological assets offsetting losses from intensified industry competition in core laboratory services H1 2025 Performance Forecast vs. Prior Period | Metric (CNY) | H1 2025 (Estimated) | H1 2024 (Prior Period) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 635 million - 702 million CNY | 849 million CNY | -25.2% to -17.3% | | Net Profit Attributable to Shareholders | 50.32 million - 75.49 million CNY | -169.74 million CNY | Turned Profitable | | Non-recurring Net Profit Attributable to Shareholders | 18.83 million - 28.25 million CNY | -198.39 million CNY | Turned Profitable | - The company's core laboratory services business is expected to incur a net loss, with fair value changes in biological assets and financial management income being the primary contributors to profitability this period45 H1 2025 Estimated Non-recurring Net Profit Breakdown | H1 2025 Non-recurring Net Profit Composition (Estimated) | Amount (CNY) | | :--- | :--- | | Net Profit from Laboratory Services | -77.47 million to -116.20 million CNY | | Contribution from Fair Value Changes in Biological Assets | 70.32 million to 105.47 million CNY | | Contribution from Financial Management Income | 25.99 million to 38.98 million CNY | Prior Period Performance In H1 2024, the company achieved operating revenue of 849.36 million CNY and reported a net loss attributable to shareholders of 169.74 million CNY, primarily due to a 235.36 million CNY loss from fair value changes in biological assets, while core laboratory services incurred a relatively smaller loss H1 2024 Prior Period Performance | Metric (CNY) | H1 2024 | | :--- | :--- | | Operating Revenue | 849.36 million CNY | | Net Profit Attributable to Shareholders | -169.74 million CNY | | Non-recurring Net Profit Attributable to Shareholders | -198.39 million CNY | | Earnings Per Share | -0.23 CNY | - The non-recurring net loss in the prior period was primarily composed of: net loss from laboratory services of 15.24 million CNY, net loss from fair value changes in biological assets of 235.36 million CNY, and net profit contribution from financial management income of 52.21 million CNY6 Explanation of Performance Changes The company attributes the performance change to intensified industry competition reducing main business revenue and gross margin, leading to losses, while stable biological asset prices and natural growth positively impacted fair value changes, reversing prior period losses - Intensified industry competition compressed profit margins on sales orders, leading to a decrease in operating revenue and gross margin, causing the laboratory services business to turn from profit to loss7 - Unlike the significant decline in biological asset market prices in the prior year, the market price of the company's biological assets remained stable this reporting period, with fair value changes from natural growth positively impacting performance7 Risk Warning and Other Matters The company confirms no significant uncertainties affecting the accuracy of this performance forecast but reminds investors that the disclosed data is preliminary, with final financial figures subject to the official H1 2025 report - The company declares no significant uncertainties affecting the accuracy of this performance forecast8 - The forecast data represents preliminary calculations, and final financial figures will be based on the company's officially disclosed H1 2025 semi-annual report9